BioSpace News Archive

The data showed that a subcutaneous injection of 300 mg of inclisiran given at Day-1 and Day-90 lowered LDL-cholesterol (LDL-C) at Day-180 by more than 50% in patients with atherosclerotic cardiovascular disease (ASCVD) and those considered ASCVD-risk equivalents, regardless of whether those patients had diabetes.

Plans to add nearly 2,500 acres of mulberry to support commercialization scale up of the Company’s recombinant spider silk technology

Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.

NV-5138 is a specific and direct activator of mTORC1, a cellular pathway required for the efficacy of many rapid acting antidepressants

Extension builds on collaboration established in 2014

2018 Awards Contribute to PanCAN’s $48 Million Research Investment

Program will Aim to Further Characterize the Functional Impact of Nektar Immunotherapies

Integrated national platform aims to accelerate employer adoption of bundled payments

Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates

Elligo Health Research has partnered with HealthiVibe. The goal of the partnership is to bring the patient to the center of the clinical trial experience.